Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Moderna, Inc. before investing.

In this article, we go over a few key elements for understanding Moderna, Inc.’s stock price such as:

• Moderna, Inc.’s current stock price and volume
• Why Moderna, Inc.’s stock price changed recently
• Upgrades and downgrades for MRNA from analysts
• MRNA’s stock price momentum as measured by its relative strength

About Moderna, Inc. (MRNA)

Before we jump into Moderna, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Moderna, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Moderna, Inc..

Moderna, Inc.’s Stock Price as of Market Close

As of May 20, 2025, 12:47 PM, CST, Moderna, Inc.’s stock price was $27.920.

Moderna, Inc. is up 5.8% from its previous closing price of $26.390.

During the last market session, Moderna, Inc.’s stock traded between $26.470 and $30.300. Currently, there are approximately 386.00 million shares outstanding for Moderna, Inc..

Moderna, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Moderna, Inc. Stock Price History

Moderna, Inc.’s (MRNA) price is currently down 2.17% so far this month.

During the month of May, Moderna, Inc.’s stock price has reached a high of $30.300 and a low of $23.155.

Over the last year, Moderna, Inc. has hit prices as high as $170.470 and as low as $23.150. Year to date, Moderna, Inc.’s stock is down 32.85%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Moderna, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 19, 2025, there were 4 analysts who downgraded Moderna, Inc.’s stock and 5 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Moderna, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Moderna, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Moderna, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Moderna, Inc. (MRNA) by visiting AAII Stock Evaluator.

Relative Price Strength of Moderna, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 19, 2025, Moderna, Inc. has a weighted four-quarter relative price strength of -31.20%, which translates to a Momentum Score of 5 and is considered to be Very Weak.

Want to learn more about how Moderna, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Moderna, Inc. Stock Price: Bottom Line

As of May 20, 2025, Moderna, Inc.’s stock price is $27.920, which is up 5.8% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Moderna, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.